Clinical Trials Logo

Analgesics clinical trials

View clinical trials related to Analgesics.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04489420 Terminated - Clinical trials for Glioblastoma Multiforme

Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM

CYNK001GBM01
Start date: October 1, 2020
Phase: Phase 1
Study type: Interventional

This study will find the maximum safe dose (MSD) or maximum tolerated dose (MTD) of CYNK-001 which are NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy for the systemic cohort (IV) (intravenous). The intratumoral cohort (IT) will not be giving lymphodepletion. The safety of this treatment will be evaluated, and researchers want to learn if NK cells will help in treating recurrent glioblastoma multiforme.